Intervacc AB (FRA:2E9) Total Operating Expense: €7.28 Mil (TTM As of Mar. 2026)


FRA:2E9 Intervacc AB FRA:2E9
63 GF Score
Price €0.10
GF Value €0.08
! 5 Warning Signs
View Full Analysis

What is Intervacc AB Total Operating Expense?

Intervacc AB FRA:2E9 +0.31% 63 Total Operating Expense is €7.28 Mil as of Mar. 2026. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review.

Intervacc AB's Total Operating Expense for the three months ended in Mar. 2026 was €2.16 Mil. Intervacc AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €7.28 Mil.

Intervacc AB Total Operating Expense Related Terms

Intervacc AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Intervacc AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intervacc AB Total Operating Expense Chart

Intervacc AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.47 6.17 7.13 6.41 6.62

Intervacc AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.79 1.52 1.80 2.16
FRA:2E9
63GF Score
Intervacc AB FRA:2E9
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intervacc AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €7.28 Mil mean?
Intervacc AB (FRA:2E9) has a Total Operating Expense of €7.28 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Intervacc AB and its competitors.
Is Intervacc AB's Total Operating Expense too high?
Intervacc AB's current Total Operating Expense is €7.28 Mil. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Total Operating Expense compare to VRTX and REGN?
Intervacc AB's Total Operating Expense of €7.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Intervacc AB and its competitors. Intervacc AB's current Total Operating Expense is €7.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Total Operating Expense of €7.28 Mil. The stock's GF Value™ is €0.08, compared to a current price of €0.10 — trading 22.3% above its estimated fair value. The current Total Operating Expense is €7.28 Mil. Intervacc AB's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Total Operating Expense is €7.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intervacc AB (FRA:2E9) Overvalued in 2026?

Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued. The current stock price of €0.10 is trading 22.3% above its estimated GF Value™ of €0.08.

Key valuation signals for FRA:2E9:

  • Total Operating Expense: €7.28 Mil
  • GF Value™: €0.08 vs. price of €0.10 (22.3% above fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intervacc AB Business Description

Other Exchanges IVACC:Sweden
Address Vastertorpsvagen 135, Hagersten, Stockholm, SWE, S-129 44
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score

Get the complete analysis for FRA:2E9

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price
€0.08
GF Value